Exercise of Options, Director Dealing and TVR

One Health Group PLC

29 October 2026

 

One Health Group plc

("One Health", the "Company" or the “Group”)

Exercise of Options, Director Dealing and TVR

One Health Group plc (AIM: OHGR), the independent provider of NHS-funded surgical procedures for patients referred from the NHS through ‘Patient Choice’, announces that on 29 October 2026, Adam Binns, Chief Executive Officer, exercised 100,035 options over ordinary shares of 0.5 pence each in the Company ("Ordinary Shares"). These share options were granted on 17 February 2021 under the Company's approved EMI scheme to employees.

Adam Binns has subsequently sold 27,000 Ordinary Shares to cover the exercise cost and personal tax liabilities arising from the exercise. Consequently, Adam has increased his total beneficial interest in the Company from 14,457 to 87,492 Ordinary Shares Details are set out below:

Director	Options exercised	Exercise price	Shares sold to satisfy tax liabilities	Sale price	Total shareholding post-exercise and sale	Total shareholding as % of issued share capital
Adam Binns	100,035	66.7p	27,000	309p	87,492	0.6%

Admission and Total Voting Rights

Pursuant to the exercise of the share options, an application has been made to the London Stock Exchange for admission to trading on AIM of 100,035 new Ordinary Shares (“Admission”). It is expected that Admission will become effective at 8.00 a.m. on 30 October 2026. The new Ordinary Shares  will, when issued,  be credited as fully paid and rank pari passu in all respects with the existing issued Ordinary Shares.

Following Admission, the total number of ordinary shares and voting rights in the Company will be 13,931,868. The Company does not hold any shares in treasury.

The above figure of 13,931,868 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

If you wish to keep up to date on Company news please email: [e-mail]

For more information, please contact:

One Health Group plc Derek Bickerstaff, Chairman Adam Binns, CEO		www.onehealth.co.uk/investors Via Walbrook PR
Panmure Liberum (Nominated Adviser and Broker) Emma Earl, Will Goode, Mark Rogers Rupert Dearden		Tel: [phone]
Walbrook PR (Media & Investor Relations) Alice Woodings / Paul McManus / Rachel Broad	Tel: [phone] or [e-mail] Mob: [phone] /                                                                     [phone]

About One Health Group plc (www.onehealth.co.uk)

One Health engages 88 NHS Consultants (excluding anaesthetists) who sub-specialise in the various surgeries offered by the Company, through a growing network of community-based outreach clinics and surgical operating locations. One Health continues to deliver strong growth and in the year to March 2026 provided much needed care to almost 19,000 new patients, through over 50,000 consultations and over 8,000 surgical procedures. One Health deploys surgeons and anaesthetists that are mostly employed by the NHS, on a subcontracted basis. It currently works with over 140 professionals across 14 independent hospitals and 40 outreach clinics. Within these community-based outreach clinics all consultations and post-operative physiotherapy is delivered where required, reducing patient inconvenience, excess travel and distress.

One Health's activities are focused on areas where NHS patient needs are under-supplied by the local NHS service, population density is relatively high and the level of private medical insurance or the ability to self-fund is relatively low. Currently, the Company's activities are focused in Yorkshire, Lincolnshire, Derbyshire, Nottinghamshire and Leicestershire. Revenue is derived from 29 ICBs across England as well as contracts with local NHS trusts to transfer their internal waiting list patients to One Health for quicker treatment.

One Health's business model has focused to date on four main areas: orthopaedics, spine, general surgery and gynaecology, which represent the majority of the national waiting list, with urology introduced at the end of FY25.

Spine and orthopaedics are particularly attractive areas for One Health as the Directors believe that they benefit from powerful growth drivers in terms of an ageing demographic, physical inactivity and an increasing proportion of the population being categorised as obese. Within orthopaedics, the most common surgeries performed by One Health are knee and hip replacements.

Online investor presentation

Click below for the latest online presentation by Derek Bickerstaff, Chairman and Adam Binns, Chief Executive Officer, which offers insights into the Company’s financial results for the year ended 31 March 2026, growth strategy and long-term vision: https://www.investormeetcompany.com/meetings/investor-presentation-1068

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Adam Binns
2	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	One Health Group plc
b)	LEI	984500DC689F5BAD8732
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Options over Ordinary Shares of 0.5 pence each
	Identification code	GB00BNNT0595
b)	Nature of the transaction	Exercise of options and partial sale of the resultant shares
c)	Price(s) and volumes(s)	As set out in d) below
d)	Aggregated information
	Exercise of options
	Volume	100,035
	Price	66.7p
	Sale of Ordinary Shares
	Volume	27,000
	Price	309p
e)	Date of the transaction	29 October 2026
f)	Place of the transaction	London Stock Exchange

 

END